Results 61 to 70 of about 740,069 (270)

NRASQ61R Expression in Lymphatic Endothelial Cells Causes Enlarged Vessels, Hemorrhagic Chylous Effusions, and High Mortality in a Mouse Model of Kaposiform Lymphangiomatosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Kaposiform lymphangiomatosis (KLA) is an aggressive complex lymphatic anomaly. Patients exhibit malformed lymphatic vessels and often develop hemorrhagic effusions and elevated angiopoietin‐2 (Ang‐2) levels. A somatic NRAS p.Q61R (NRASQ61R) mutation has been associated with KLA.
C. Griffin McDaniel, Patricia Pastura, Joshua P. Scallan, Timothy D. Le Cras   +3 more
wiley   +1 more source

Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT

Cancer Reports, 2022
Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment option in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN ...
Joël Guigay, Emmanuel Chamorey, Gautier Lefebvre, Maciej Rotarski, Jean‐Philippe Wagner, Emmanuel Blot, Marc Alfonsi, Audrey Seronde, Jeltje Schulten, Frédéric Peyrade, Christophe Le Tourneau   +10 more
doaj   +1 more source

Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies

Haematologica, 2022
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment of non-hematologic malignancies. Many patient-related variables (e.g., age, tumor type, number of prior chemotherapy cycles, amount of bone marrow tumor involvement ...
David J. Kuter
doaj   +1 more source

Dose-response between frequency of breaks in sedentary time and glucose control in type 2 diabetes: a proof of concept study [PDF]

, 2019
Objectives This study aimed to investigate dose-response between frequency of breaks in sedentary time and glucose control.DesignRandomised three-treatment, two-period balanced incomplete block trial.MethodsTwelve adults with type 2 diabetes (age, 60 ...
Chastin, Sebastien F.M., Collier, Andrew, Hewitt, Allan, Kirk, Alison F., McMillan, Kathryn A., Paing, Aye C.   +5 more
core   +2 more sources

The Fate (Outcome) of Clinically Apparent Single Lesion and Oligofocal Nephroblastomatosis Treated According to SIOP/GPOH Protocols for Wilms Tumor

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background The management of clinically apparent single lesions or oligofocal nephroblastomatosis, a facultative precursor of nephroblastoma, remains debated. Methods We retrospectively analyzed 37 patients with clinically apparent single or oligofocal nephroblastomatosis (two to three lesions per kidney) among 2347 patients registered between
Nils Welter, Jens‐Peter Schenk, Jenny Wegert, Manfred Gessler, Leo Kager, Stefan Wagenpfeil, Marina Müller, Jean‐Michel Wolff, Joerg Fuchs, Steven W. Warmann, Clemens‐Magnus Meier, Jochen Hubertus, Christian Rübe, Christian Vokuhl, Patrick Melchior, Lena Tschirner, Norbert Graf, Rhoikos Furtwängler   +17 more
wiley   +1 more source

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials [PDF]

Cancer Science, 2017
Phase 1 trials of molecularly targeted agents (MTA) often do not use toxicity data beyond the first cycle of treatment to determine a recommended phase 2 dose (RP2D). We investigated the potential utility of longitudinal relative dose intensity (RDI) that may be a better new way of determining a more accurate RP2D as a lower dose that is presumably ...
Akihiro Hirakawa, Kan Yonemori, Fumie Kinoshita, Yumiko Kobayashi, Hitomi S. Okuma, Asuka Kawachi, Kenji Tamura, Yasuhiro Fujiwara, Larry Rubinstein, Pamela Jo Harris, Naoko Takebe   +10 more
openaire   +2 more sources

Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study [PDF]

, 2018
Background: Chemotherapy-induced neutropenia (CIN) places patients at risk of life-threatening infections. While reduction of chemotherapy dose or delay of the subsequent treatment cycle and, consequently, reduction of relative dose intensity (RDI) may ...
Bosly, André, Constenla, Manuel, Jackisch, Christian, Leonard, Robert, Paridaens, Robert, Pettengell, Ruth, Schwenkglenks, Matthias, Szucs, Thomas   +7 more
core  

Feasibility and Safety of High‐Dose Proton Re‐Irradiation in Recurrent Pediatric Central Nervous System Tumors: A Single‐Institution Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Pediatric central nervous system (CNS) tumors often recur despite multimodality therapy. Although re‐irradiation (re‐RT) has historically been limited by concerns for severe late toxicities, modern techniques have renewed interest in this approach. Proton therapy provides dosimetric advantages that may enable curative re‐treatment with
Jin‐Ho Song, Jonathan Baron, Carlos Chavez Perez, Sidharth Ramesh, Jane Minturn, Kavita A. Desai, Amish C. Shah, Jean M. Belasco, Kristina A. Cole, Michael J. Fisher, Phillip B. Storm, Peter M. Madsen, Goldie Kurtz, Robert A. Lustig, Christine Hill‐Kayser, Michael J. LaRiviere   +15 more
wiley   +1 more source

Sex differences in toxicity and outcomes in patients with sarcoma treated in the perioperative setting at a comprehensive cancer center

Frontiers in Oncology
BackgroundThere is an unmet need of personalized strategies taking into account the influence of sex on treatment. Toxicities commonly lead to dose reductions or delays, which may impact outcomes.
Ilaria Tortorelli, Ilaria Tortorelli, Benedetta Chiusole, Fabio Murtas, Fabio Murtas, Antonella Galiano, Maital Bolshinsky, Selma Ahcene-Djaballah, Chiara De Toni, Salvatore Vizzaccaro, Marco Maruzzo, Umberto Basso, Alberto Banzato, Marina Coppola, Sara Lonardi, Vittorina Zagonel, Antonella Brunello   +16 more
doaj   +1 more source

Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More

Current Oncology, 2023
Aim: The key purposes of the treatment of metastatic malignancies are to extend survival and maintain the quality of life. Recently it has been emphasized in the scientific literature that the maintenance of maximal dose intensity is not always ...
Balázs Pécsi, László Mangel
doaj   +1 more source